ArticleMediators of inflammation2026
Demethoxycurcumin Alleviates Lipopolysaccharide-Induced Acute Lung Injury via Nrf2-Mediated Anti-Inflammation and Ferroptosis Inhibition.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Demethoxycurcumin Alleviates Lipopolysaccharide-Induced Acute Lung Injury via Nrf2-Mediated Anti-Inflammation and Ferroptosis Inhibition.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSepsis-induced acute lung injury (SI-ALI) represents a life-threatening condition driven by dysregulated immune responses and redox imbalance. Demethoxycurcumin (DMC), a bioactive analog of curcumin, exhibits marked anti-inflammatory and free radical-scavenging capacities. Despite its potential, the precise molecular pathways through which DMC mitigates SI-ALI pathogenesis have yet to be fully elucidated.
methodsSI-ALI was induced in mice through lipopolysaccharide (LPS) administration. Lung injury was assessed by histopathological analysis and measurement of wet-to-dry (W/D) weight ratios. Oxidative stress markers were quantified using ELISA, and inflammatory cytokine mRNA levels were analyzed by RT-PCR. Ferroptosis-related proteins and Nrf2 pathway activation were evaluated through Western blotting and immunofluorescence. Mitochondrial ultrastructure was examined via transmission electron microscopy (TEM). The involvement of the Nrf2 pathway was further confirmed by using the Nrf2 inhibitor ML385.
resultsDMC treatment significantly alleviated lung injury in a dose-dependent manner, improving histopathology and reducing W/D weight ratios. It attenuated inflammation by suppressing IL-6, TNF-α, and IL-1β expression and restored oxidative balance by enhancing glutathione (GSH) levels while decreasing malondialdehyde (MDA). Moreover, DMC upregulated glutathione peroxidase 4 (GPX4) and SLC7A11, downregulated cyclooxygenase-2 (COX2) and ACSL4, reduced nonheme iron and 4-hydroxynonenal (4-HNE) production, and improved mitochondrial morphology, collectively demonstrating its inhibitory effects on ferroptosis. Nrf2 inhibition partially reversed these protective effects, underscoring the central role of the Nrf2 pathway in DMC's mechanism of action.
conclusionDMC ameliorates SI-ALI by mitigating inflammation and ferroptosis through Nrf2 pathway activation, suggesting a potential therapeutic strategy for SI-ALI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.